Specifically, dopamine agonists are usually the first choice for hormonal and tumor size control in PRL-secreting PAs, while somatostatin analogues are often used for GH-producing PAs and post-transsphenoidal surgery treatment [3]. The gene discussed is GH1; the disease is gonorrhea.